CYTRX CORP
S-1, EX-27.2, 2000-06-21
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: CYTRX CORP, S-1, EX-27.1, 2000-06-21
Next: CYTRX CORP, S-1, EX-27.3, 2000-06-21



<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<RESTATED>

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               DEC-31-1998
<CASH>                                       8,855,375
<SECURITIES>                                 6,417,066
<RECEIVABLES>                                  383,249
<ALLOWANCES>                                         0
<INVENTORY>                                     10,935
<CURRENT-ASSETS>                            15,677,002
<PP&E>                                         799,439
<DEPRECIATION>                               (604,409)
<TOTAL-ASSETS>                              16,641,568
<CURRENT-LIABILITIES>                        1,949,123
<BONDS>                                              0
                                0
                                          0
<COMMON>                                         8,237
<OTHER-SE>                                  14,680,311
<TOTAL-LIABILITY-AND-EQUITY>                16,641,568
<SALES>                                        350,789
<TOTAL-REVENUES>                             2,113,536
<CGS>                                                0
<TOTAL-COSTS>                                  187,047
<OTHER-EXPENSES>                             9,617,897
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              45,888
<INCOME-PRETAX>                            (7,737,296)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (7,737,296)
<DISCONTINUED>                               2,943,937
<EXTRAORDINARY>                              (325,120)
<CHANGES>                                            0
<NET-INCOME>                               (5,118,479)
<EPS-BASIC>                                      (.67)
<EPS-DILUTED>                                    (.67)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission